Tirzepatide vial crystals: what they mean

A vial of tirzepatide from the grey market that shows wall-sticking residue, white crystals, or a cloudy appearance is not behaving normally. The FDA-approved prescribing information for Mounjaro states plainly that the solution should appear ^[1] "clear and colorless to slightly yellow" before injection, and instructs patients not to use it if particulate matter or discoloration is present. Crystallization is one of the most visible signs that something has gone wrong with the formulation, storage, or manufacturing of a peptide product.

What tirzepatide is supposed to look like

Licensed Mounjaro and Zepbound pens contain tirzepatide as a sterile aqueous solution formulated with specific buffers, stabilizers, and pH controls that keep the molecule in solution. The prescribing information describes ^[1] the finished product as a clear liquid ranging from colorless to faintly yellow. Any turbidity, floating particles, or solid material clinging to vial walls sits outside that description. The rule for patients on the FDA label is straightforward: if it does not look right, do not inject it.

Why peptides crystallize or precipitate

Peptide medicines are physically fragile. Research published in Molecular Pharmaceutics shows that fibril and aggregate formation in pharmaceutical peptides depends on pH, ionic strength, temperature, agitation, and contact with surfaces^[2]. Conditions that deviate from the controlled environment the manufacturer designed the formulation around can trigger a cascade. Even small changes in pH can shorten the lag phase before fibrils begin to form.

For a grey-market vial reconstituted at home, every one of those variables is uncertain. The starting material may not be pharmaceutical-grade tirzepatide at all. The water used for reconstitution may not be bacteriostatic. The pH of the resulting solution is unknown without testing. The cold chain during shipping may have been broken. The concentration written on the label may not reflect the actual amount dissolved. Any of these can independently drive the visible change a user sees on the vial wall.

Is it crystals, mould, or something else

Crystallization and microbial contamination look different under magnification, but distinguishing them without laboratory equipment is not reliable. Crystalline precipitate tends to have a geometric, glassy quality. Mould or bacterial growth tends to be irregular, fibrous, or spreading. Either finding is a reason not to use the product. A separate study identified a widespread, previously uncharacterised impurity in mass-compounded tirzepatide products formed by a chemical reaction between tirzepatide and certain vitamin B12 analogs that some vendors add to their formulations^[5]. That impurity is not visible to the naked eye, which means a vial that looks clear can still contain chemical contaminants the user cannot detect.

What the safety data says about compounded products

A 2026 pharmacovigilance analysis of FDA adverse event reports found that compounded GLP-1 receptor agonists showed significantly higher odds of contamination reports, preparation errors, and hospitalization compared to branded formulations^[3]. The hospitalization odds ratio for compounded products was 2.35 compared to licensed versions. A position statement from the endocrine and metabolism network of the American College of Clinical Pharmacy noted that compounded incretin products do not undergo FDA approval, which means their sterility, potency, and formulation stability are not independently verified^[4].

The absence of regulatory oversight matters here because the quality controls that prevent visible physical changes, sterility failures, and impurity formation in licensed medicines are exactly the controls compounded products lack. A user who sees something odd in their vial is seeing a downstream symptom of that gap.

What to do if your vial looks abnormal

Do not inject a vial with visible particles, wall-sticking residue, cloudiness, or any appearance outside clear and essentially colorless to faintly yellow. Discard it. The appropriate next step is to discuss access to licensed tirzepatide with a prescriber who can advise on whether you qualify for Mounjaro or Zepbound through a legitimate channel in your jurisdiction. Country-by-country regulatory status is on the regulation pages for each peptide.

If you are already injecting grey-market tirzepatide and you experience unexpected symptoms, including injection-site reactions, fever, or gastrointestinal symptoms outside the expected class profile, contact a healthcare provider promptly. A vial that looked fine is not a guarantee the product was safe: as the impurity data show, chemical contamination can be present with no visible indicator.

What we do not yet know

The published pharmacovigilance data on compounded GLP-1 products covers a broad set of preparations, not tirzepatide alone, and adverse-event databases record association rather than causation. There is no peer-reviewed dataset that links specific visual findings in grey-market tirzepatide vials to specific clinical outcomes. The community thread this article draws on as a signal is anecdotal and involves a small number of users comparing photographs. What the regulatory-grade data does tell us is that the risk profile of compounded products is meaningfully higher than the licensed alternatives, and a vial that does not pass visual inspection is a data point worth taking seriously.